[
  {
    "ts": null,
    "headline": "LA County Jury Hits Johnson & Johnson with Nearly $1 Billion Verdict",
    "summary": "LOS ANGELES, October 07, 2025--A Los Angeles County jury has returned damages totaling $966 million, including $950 million in punitive damages, to the family of Mae Moore, who died of mesothelioma in 2021 after using Johnson & Johnson’s iconic baby powder.",
    "url": "https://finnhub.io/api/news?id=6d058011145c64d9770d7ee05319977ee22d9a72c03b9e1cf46ff9f7de7d6c1c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759868340,
      "headline": "LA County Jury Hits Johnson & Johnson with Nearly $1 Billion Verdict",
      "id": 137007975,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "LOS ANGELES, October 07, 2025--A Los Angeles County jury has returned damages totaling $966 million, including $950 million in punitive damages, to the family of Mae Moore, who died of mesothelioma in 2021 after using Johnson & Johnson’s iconic baby powder.",
      "url": "https://finnhub.io/api/news?id=6d058011145c64d9770d7ee05319977ee22d9a72c03b9e1cf46ff9f7de7d6c1c"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Edge Down Late Afternoon",
    "summary": "Health care stocks edged lower late Tuesday afternoon, with the NYSE Health Care Index and the Healt",
    "url": "https://finnhub.io/api/news?id=e56d8938bc9062ca5aefbd8d375463e339a0f05b9b58c10f8b0d7c1580487c67",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759866669,
      "headline": "Sector Update: Health Care Stocks Edge Down Late Afternoon",
      "id": 137002646,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Health care stocks edged lower late Tuesday afternoon, with the NYSE Health Care Index and the Healt",
      "url": "https://finnhub.io/api/news?id=e56d8938bc9062ca5aefbd8d375463e339a0f05b9b58c10f8b0d7c1580487c67"
    }
  },
  {
    "ts": null,
    "headline": "The Zacks Analyst Blog Highlights Microsoft, Amazon.com, Johnson & Johnson and Willis Lease Finance",
    "summary": "Zacks Analyst Blog highlights Microsoft, Amazon, Johnson & Johnson, and Willis Lease Finance as analysts weigh AI growth, pharma resilience, and niche leasing strength.",
    "url": "https://finnhub.io/api/news?id=8bf34fd1d27c7df8b7a0f36e777600f3a5900514a1baed879b85d5d8292bedb3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759844040,
      "headline": "The Zacks Analyst Blog Highlights Microsoft, Amazon.com, Johnson & Johnson and Willis Lease Finance",
      "id": 136998867,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Zacks Analyst Blog highlights Microsoft, Amazon, Johnson & Johnson, and Willis Lease Finance as analysts weigh AI growth, pharma resilience, and niche leasing strength.",
      "url": "https://finnhub.io/api/news?id=8bf34fd1d27c7df8b7a0f36e777600f3a5900514a1baed879b85d5d8292bedb3"
    }
  },
  {
    "ts": null,
    "headline": "Prudential Financial (PRU): Assessing Valuation as Fundamental Challenges Draw Renewed Investor Scrutiny",
    "summary": "Prudential Financial (PRU) has landed in the spotlight as investors take a closer look at its fundamentals. This follows news of shrinking net premiums, tepid book value growth, and a rising debt-to-equity ratio. See our latest analysis for Prudential Financial. Amid Prudential Financial’s ongoing balance sheet concerns and last week’s addition of Johnson & Johnson CFO Joseph Wolk to its board, the stock has struggled to gain momentum. While the share price return has lagged this year,...",
    "url": "https://finnhub.io/api/news?id=6b2147e6656b06e206e9fbaf9413bd1d9fe5cc2487491c9a18785a9f94428003",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759842923,
      "headline": "Prudential Financial (PRU): Assessing Valuation as Fundamental Challenges Draw Renewed Investor Scrutiny",
      "id": 136998868,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Prudential Financial (PRU) has landed in the spotlight as investors take a closer look at its fundamentals. This follows news of shrinking net premiums, tepid book value growth, and a rising debt-to-equity ratio. See our latest analysis for Prudential Financial. Amid Prudential Financial’s ongoing balance sheet concerns and last week’s addition of Johnson & Johnson CFO Joseph Wolk to its board, the stock has struggled to gain momentum. While the share price return has lagged this year,...",
      "url": "https://finnhub.io/api/news?id=6b2147e6656b06e206e9fbaf9413bd1d9fe5cc2487491c9a18785a9f94428003"
    }
  },
  {
    "ts": null,
    "headline": "TREMFYA® (guselkumab) is first and only IL-23 inhibitor to demonstrate sustained clinical and endoscopic outcomes with a fully subcutaneous regimen through 48 weeks in ulcerative colitis",
    "summary": "Johnson & Johnson (NYSE: JNJ) today announced new 48-week data from the Phase 3 ASTRO study evaluating TREMFYA® (guselkumab) subcutaneous (SC) induction and maintenance therapy in adults with moderately to severely active ulcerative colitis (UC). These data show clinically meaningful rates of clinical and endoscopic remission, making TREMFYA® the first and only IL-23 inhibitor to demonstrate robust results with a fully SC regimen.1 The findings are among 20 Johnson & Johnson abstracts being pres",
    "url": "https://finnhub.io/api/news?id=d55f5c0dce3d962221b8f469a395beb0ba2909ca6e46b49a6b2d938931ce6c73",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759838700,
      "headline": "TREMFYA® (guselkumab) is first and only IL-23 inhibitor to demonstrate sustained clinical and endoscopic outcomes with a fully subcutaneous regimen through 48 weeks in ulcerative colitis",
      "id": 136998870,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE: JNJ) today announced new 48-week data from the Phase 3 ASTRO study evaluating TREMFYA® (guselkumab) subcutaneous (SC) induction and maintenance therapy in adults with moderately to severely active ulcerative colitis (UC). These data show clinically meaningful rates of clinical and endoscopic remission, making TREMFYA® the first and only IL-23 inhibitor to demonstrate robust results with a fully SC regimen.1 The findings are among 20 Johnson & Johnson abstracts being pres",
      "url": "https://finnhub.io/api/news?id=d55f5c0dce3d962221b8f469a395beb0ba2909ca6e46b49a6b2d938931ce6c73"
    }
  },
  {
    "ts": null,
    "headline": "Icotrokinra data in ulcerative colitis show potential for a standout combination of therapeutic benefit and a favorable safety profile in once-daily pill",
    "summary": "Johnson & Johnson (NYSE: JNJ) today announced additional Week 12 results from the Phase 2b ANTHEM-UC study of icotrokinra, a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor, in adults with moderately to severely active ulcerative colitis (UC). The study met its primary endpoint, with all once-daily icotrokinra dose groups achieving clinical responsea at Week 12 and showing clinically meaningful improvements versus placebo across key secondary endpo",
    "url": "https://finnhub.io/api/news?id=63fd49c626ea81aff215ed2c020d329627033933faf029d1d850959a2fdd2956",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759838700,
      "headline": "Icotrokinra data in ulcerative colitis show potential for a standout combination of therapeutic benefit and a favorable safety profile in once-daily pill",
      "id": 136998869,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE: JNJ) today announced additional Week 12 results from the Phase 2b ANTHEM-UC study of icotrokinra, a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor, in adults with moderately to severely active ulcerative colitis (UC). The study met its primary endpoint, with all once-daily icotrokinra dose groups achieving clinical responsea at Week 12 and showing clinically meaningful improvements versus placebo across key secondary endpo",
      "url": "https://finnhub.io/api/news?id=63fd49c626ea81aff215ed2c020d329627033933faf029d1d850959a2fdd2956"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Unveils New Data Demonstrating Superior Clarity of Vision and Comfort of ACUVUE OASYS MAX 1-Day for ASTIGMATISM, and MULTIFOCAL for ASTIGMATISM Contact Lenses",
    "summary": "Johnson & Johnson (NYSE: JNJ) – Johnson & Johnson*, a global leader in eye health, announced new data on the ACUVUE OASYS MAX 1-Day for ASTIGMATISM contact lenses which showed higher end-of-day comfort^ as compared to Dailies Total1® for Astigmatism. The data will be presented at the American Academy of Optometry's annual meeting in Boston. Other data being showcased includes ACUVUE OASYS MAX 1-Day MULTIFOCAL for ASTIGMATISM extends daily disposable multifocal contact lens options to a new popul",
    "url": "https://finnhub.io/api/news?id=b2ea6253f149046ffeb25302ff57b97d1662b4cab0ea7ac4acbeec3952ebc8c5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759838400,
      "headline": "Johnson & Johnson Unveils New Data Demonstrating Superior Clarity of Vision and Comfort of ACUVUE OASYS MAX 1-Day for ASTIGMATISM, and MULTIFOCAL for ASTIGMATISM Contact Lenses",
      "id": 136998871,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE: JNJ) – Johnson & Johnson*, a global leader in eye health, announced new data on the ACUVUE OASYS MAX 1-Day for ASTIGMATISM contact lenses which showed higher end-of-day comfort^ as compared to Dailies Total1® for Astigmatism. The data will be presented at the American Academy of Optometry's annual meeting in Boston. Other data being showcased includes ACUVUE OASYS MAX 1-Day MULTIFOCAL for ASTIGMATISM extends daily disposable multifocal contact lens options to a new popul",
      "url": "https://finnhub.io/api/news?id=b2ea6253f149046ffeb25302ff57b97d1662b4cab0ea7ac4acbeec3952ebc8c5"
    }
  },
  {
    "ts": null,
    "headline": "J&J presents data highlighting superiority of its lenses for astigmatism",
    "summary": "Johnson & Johnson announces new data demonstrating the superiority of its ACUVUE OASYS MAX 1-Day for Astigmatism lenses in terms of comfort and vision quality compared to Dailies Total1 for...",
    "url": "https://finnhub.io/api/news?id=6c78707b48f74a14b66a6f7ee12d2690c56f141207fc25a81187b13dc352e3e4",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759826527,
      "headline": "J&J presents data highlighting superiority of its lenses for astigmatism",
      "id": 136998078,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Johnson & Johnson announces new data demonstrating the superiority of its ACUVUE OASYS MAX 1-Day for Astigmatism lenses in terms of comfort and vision quality compared to Dailies Total1 for...",
      "url": "https://finnhub.io/api/news?id=6c78707b48f74a14b66a6f7ee12d2690c56f141207fc25a81187b13dc352e3e4"
    }
  },
  {
    "ts": null,
    "headline": "1 Reason I'm Watching Intuitive Surgical Stock in 2026",
    "summary": "The surgical robotics pioneer could cement its leading position for years to come.",
    "url": "https://finnhub.io/api/news?id=c13be11c71d4c7daf4b699bc22d5f84e8fc849999765d76dbc7793edd323479a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759821960,
      "headline": "1 Reason I'm Watching Intuitive Surgical Stock in 2026",
      "id": 136998872,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The surgical robotics pioneer could cement its leading position for years to come.",
      "url": "https://finnhub.io/api/news?id=c13be11c71d4c7daf4b699bc22d5f84e8fc849999765d76dbc7793edd323479a"
    }
  }
]